Trials / Recruiting
RecruitingNCT07107230
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 380 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-95437446 | JNJ-95437446 will be administered. |
Timeline
- Start date
- 2025-07-15
- Primary completion
- 2027-11-18
- Completion
- 2028-04-24
- First posted
- 2025-08-06
- Last updated
- 2026-04-13
Locations
9 sites across 3 countries: United States, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07107230. Inclusion in this directory is not an endorsement.